Medicine Matters Diabetes

People with type 1 diabetes who take GLP-1 receptor agonists or SGLT2 inhibitors in clinical practice have outcomes that are mostly – but not all – in line with those in controlled trials, say researchers.

A health informatics system based on routine clinical data helps physicians to prioritize high-risk people with diabetes, deliver more equitable care, and manage healthcare capacity, report researchers.

People who have heart failure with preserved ejection fraction benefit from dapagliflozin irrespective of whether they have normal or impaired glucose metabolism, shows further analysis of DELIVER.

Screening people with type 1 diabetes for albuminuria at intervals determined by their baseline albumin excretion rate and glycated hemoglobin level reduces the time spent with undetected kidney disease, show DCCT/EDIC data.

SURMOUNT-2 trial results show bodyweight reductions with tirzepatide that rival those seen with other approved anti-obesity medications in people with type 2 diabetes.

Allowing people to try out medications for type 2 diabetes and choose their preferred one is a viable approach in the absence of a clear clinical indication, say the TriMaster investigators.

Higher glycated hemoglobin and the presence of kidney disease are associated with lower bone mineral density in people with type 1 diabetes, study results show.

The first phase 3 trial of an SGLT2 inhibitor in children and young people with type 2 diabetes shows that dapagliflozin significantly improves their glucose control – as long as they remember to take it.

SURMOUNT-2 trial results show bodyweight reductions with tirzepatide that rival those seen with other approved anti-obesity medications in people with type 2 diabetes.

Lori Berard highlights the contribution of stress to poor glycemic control and considers how healthcare providers can account for this in their practice.